A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia
A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia
The primary objective of this study is to evaluate the effectiveness of a combination drug
 containing fimasartan and statins on the control of hypertension and dyslipidemia, and the
 secondary objective is to evaluate the drug cost reduction effect, patients' satisfaction
 level and safety of the combination drug administration.
This study is designed as a non-interventional, multicenter, prospective observational study
 for patients with hypertension and dyslipidemia. If a patient voluntarily provides written
 consent to provide information for this study, the enrollment number will be assigned to
 subjects who meet the inclusion/exclusion criteria, and follow-up will be conducted for
 approximately 12 weeks. Pre-specified study-related data will be collected in the case report
 form during the observation period.

 This is an observational study, and the number or interval of subjects' visits to the
 hospital is determined by the investigators' clinical judgment under actual medical
 circumstances in principle. Whether to participate in this study will not affect the
 patients' treatment (physician's prescription or diagnostic, therapeutic decisions).

 The follow-up time points specified below indicate the time points of data collection. That
 is, the schedule of subjects' visits is freely determined by the investigators based on the
 medical condition of the subjects regardless of the follow-up time points specified in this
 protocol, but data that are generated during the study period and are deemed necessary in
 relation to the study may be collected in the case report form.
Inclusion Criteria:

 Participation in this study is possible only if all of the inclusion criteria below are
 satisfied.

 1. Patients who provide written consent on the consent form for use of personal
 information after listening to explanations regarding the purpose, method, etc. of
 this study

 2. Adult males and females aged 19 years or above

 3. Patients who correspond to one of the following:

 1. Patients who are planning to be treated with a combination drug containing fimasartan
 and statins after being newly diagnosed with essential hypertension and primary
 hypercholesterolemia

 2. Patients who are planning to switch to a combination drug of fimasartan and statins,
 among those who have been diagnosed with essential hypertension or primary
 hypercholesterolemia and are receiving hypertension treatment that is containing an
 ARB or dyslipidemia treatment that is containing a statin

 3. Patients who are planning to switch to a combination drug of fimasartan and statins,
 among those who have been diagnosed with essential hypertension and primary
 hypercholesterolemia and are receiving hypertension treatment that is containing an
 ARB and dyslipidemia treatment that is containing a statin 4. The following test
 results available within 4 weeks prior to the enrollment date

 -  Total Cholesterol (TC)

 -  HDL-C ③ Triglyceride (TG) ④ LDL-C or LDL-C (Friedewald formula*)

 -  non-HDL-C (Total cholesterol - HDL-C (mg/dL)) *LDL-C = Total
 cholesterol - HDL-C - (triglyceride/5) (mg/dL)

 Exclusion Criteria:

 Patients cannot participate in this study if any of the following exclusion criteria is
 applicable.

 1. Contraindication according to the drug labeling of the combination drug ingredients
 (fimasartan, amlodipine) for hypertension containing fimasartan

 2. Contraindication according to the drug labeling of statins (rosuvastatin,
 atorvastatin)

 3. Secondary hypertension or suspected secondary hypertension - Aortic coarctation,
 hyperaldosteronemia, renal artery stenosis, renal hypertension, pheochromocytoma,
 Cushing's syndrome, polycystic kidney disease, etc.

 4. Secondary dyslipidemia or suspected secondary dyslipidemia

 - Nephrotic syndrome, dysproteinemia, obstructive liver disease, Cushing's syndrome,
 etc.

 5. Patients currently hospitalized or scheduled to be hospitalized

 6. If an investigational drug has been administered within 12 weeks of the enrollment
 date, or if participation in another clinical study during this study participation
 period is planned

 7. Patients who are deemed ineligible for study participation at the discretion of the
 investigators for other reasons

 -